drugset / Trial / NCT07353268
Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to evaluate the safety, tolerability, and efficacy of Epalolitovoreli Monoclonal Antibody (QL1706) combined with Fruquintinib and Short-Course Radiotherapy (SCRT), compared with standard third-line therapy, in the treatment of patients with unresectable liver-metastatic pMMR/MSS colorectal cancer.
Timeline
- Start
- 2026-01-21
- Primary completion
- 2027-08-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | — | — |
| Comparator | Cetuximab | Monoclonal antibody | — | — |
| Subject | Epalolitovoreli | Unknown | 5 mg/kg | Intravenous |
| Subject | Fruquintinib | Small molecule | 3 mg | Oral |
| Subject | Fruquintinib | Small molecule | 4 mg | Oral |
| Comparator | Irinotecan | Small molecule | — | — |
| Comparator | Regorafenib | Small molecule | — | — |
| Comparator | Tipiracil | Small molecule | — | — |
| Comparator | Trifluridine | Small molecule | — | — |